FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129164530> ?p ?o ?g. }

• W2129164530 endingPage "499" @default.
• W2129164530 startingPage "493" @default.
• W2129164530 abstract "Between June 1988 and June 1994. 38 hemangioblastomas were treated with stereotactic radiosurgery (SR) at three SR centers to evaluate the efficacy and potential toxicity of this therapeutic modality as an adjuvant or alternative treatment to surgical resection.SR was performed using either a 201-cobalt source unit or a dedicated SR linear accelerator. Of the 18 primary tumors treated, 16 had no prior history of surgical resection and were treated definitively with SR and two primary lesions were subtotally resected and subsequently treated with SR. Twenty lesions were treated with SR after prior surgical failure (17 tumors) or failure after prior surgery and conventional radiotherapy (three tumors). Eight patients were treated with SR for multifocal disease (total, 24 known tumors). SR tumor volumes measured 0.05 to 12 cc (median: 0.97 cc). Minimum tumor doses ranged from 12 to 20 Gy (median: 15.5 Gy).Median follow-up from the time of SR was 24.5 months (range: 6-77 months). The 2-year actuarial over-all survival was 88 +/- 15% (95% confidence interval). Two-year actuarial freedom from progression was 86 +/- 12% (95% confidence interval). The median tumor volume of the lesions that failed to be controlled by SR was 7.85 cc (range: 3.20-10.53 cc) compared to 0.67 cc (range: 0.05-12 cc) for controlled lesions (p - 0.0023). The lesions that failed to be controlled by SR received a median minimum tumor dose of 14 Gy (range: 13-17 Gy) compared to 16 Gy (range: 12-20 Gy) for controlled lesions (p = 0.0239). Seventy-eight percent of the surviving patients remained neurologically stable or clinically improved. There were no significant permanent complications directly attributable to SR.This report documents the largest experience in the literature of the use of SR in the treatment of hemangioblastoma. We conclude that SR: (a) controls the majority of primary and recurrent hemangioblastomas; (b) offers the ability to treat multiple lesions in a single treatment session, which is particularly important for patients with Von Hippel-Lindau Syndrome; and that (c) better control rates are associated with higher doses and smaller tumor volumes." @default.
• W2129164530 created "2016-06-24" @default.
• W2129164530 creator A5001528733 @default.
• W2129164530 creator A5014328676 @default.
• W2129164530 creator A5020032572 @default.
• W2129164530 creator A5023711531 @default.
• W2129164530 creator A5035423539 @default.
• W2129164530 creator A5039465135 @default.
• W2129164530 creator A5042076336 @default.
• W2129164530 creator A5059544195 @default.
• W2129164530 creator A5061674089 @default.
• W2129164530 creator A5061884581 @default.
• W2129164530 creator A5068405060 @default.
• W2129164530 creator A5071361060 @default.
• W2129164530 creator A5088040279 @default.
• W2129164530 date "1996-06-01" @default.
• W2129164530 modified "2023-10-16" @default.
• W2129164530 title "Radiosurgery for hemangioblastoma: Results of a multiinstitutional experience" @default.
• W2129164530 cites W1543367609 @default.
• W2129164530 cites W1970144403 @default.
• W2129164530 cites W1986793532 @default.
• W2129164530 cites W1991881143 @default.
• W2129164530 cites W2010048743 @default.
• W2129164530 cites W2019288631 @default.
• W2129164530 cites W2031216023 @default.
• W2129164530 cites W2035734782 @default.
• W2129164530 cites W2057428339 @default.
• W2129164530 cites W2070021373 @default.
• W2129164530 cites W2073005838 @default.
• W2129164530 cites W2073300322 @default.
• W2129164530 cites W2118630631 @default.
• W2129164530 cites W2119337736 @default.
• W2129164530 cites W2131952575 @default.
• W2129164530 cites W2144763176 @default.
• W2129164530 cites W2158671348 @default.
• W2129164530 cites W2320263183 @default.
• W2129164530 cites W2340144735 @default.
• W2129164530 cites W4239174412 @default.
• W2129164530 cites W4241038341 @default.
• W2129164530 cites W4254202071 @default.
• W2129164530 cites W4293241248 @default.
• W2129164530 cites W4297119881 @default.
• W2129164530 doi "https://doi.org/10.1016/s0360-3016(96)80011-3" @default.
• W2129164530 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8655372" @default.
• W2129164530 hasPublicationYear "1996" @default.
• W2129164530 type Work @default.
• W2129164530 sameAs 2129164530 @default.
• W2129164530 citedByCount "95" @default.
• W2129164530 countsByYear W21291645302012 @default.
• W2129164530 countsByYear W21291645302013 @default.
• W2129164530 countsByYear W21291645302014 @default.
• W2129164530 countsByYear W21291645302015 @default.
• W2129164530 countsByYear W21291645302016 @default.
• W2129164530 countsByYear W21291645302017 @default.
• W2129164530 countsByYear W21291645302018 @default.
• W2129164530 countsByYear W21291645302019 @default.
• W2129164530 countsByYear W21291645302020 @default.
• W2129164530 countsByYear W21291645302022 @default.
• W2129164530 countsByYear W21291645302023 @default.
• W2129164530 crossrefType "journal-article" @default.
• W2129164530 hasAuthorship W2129164530A5001528733 @default.
• W2129164530 hasAuthorship W2129164530A5014328676 @default.
• W2129164530 hasAuthorship W2129164530A5020032572 @default.
• W2129164530 hasAuthorship W2129164530A5023711531 @default.
• W2129164530 hasAuthorship W2129164530A5035423539 @default.
• W2129164530 hasAuthorship W2129164530A5039465135 @default.
• W2129164530 hasAuthorship W2129164530A5042076336 @default.
• W2129164530 hasAuthorship W2129164530A5059544195 @default.
• W2129164530 hasAuthorship W2129164530A5061674089 @default.
• W2129164530 hasAuthorship W2129164530A5061884581 @default.
• W2129164530 hasAuthorship W2129164530A5068405060 @default.
• W2129164530 hasAuthorship W2129164530A5071361060 @default.
• W2129164530 hasAuthorship W2129164530A5088040279 @default.
• W2129164530 hasConcept C126322002 @default.
• W2129164530 hasConcept C141071460 @default.
• W2129164530 hasConcept C2780387249 @default.
• W2129164530 hasConcept C2989005 @default.
• W2129164530 hasConcept C44249647 @default.
• W2129164530 hasConcept C509974204 @default.
• W2129164530 hasConcept C71924100 @default.
• W2129164530 hasConceptScore W2129164530C126322002 @default.
• W2129164530 hasConceptScore W2129164530C141071460 @default.
• W2129164530 hasConceptScore W2129164530C2780387249 @default.
• W2129164530 hasConceptScore W2129164530C2989005 @default.
• W2129164530 hasConceptScore W2129164530C44249647 @default.
• W2129164530 hasConceptScore W2129164530C509974204 @default.
• W2129164530 hasConceptScore W2129164530C71924100 @default.
• W2129164530 hasIssue "3" @default.
• W2129164530 hasLocation W21291645301 @default.
• W2129164530 hasLocation W21291645302 @default.
• W2129164530 hasOpenAccess W2129164530 @default.
• W2129164530 hasPrimaryLocation W21291645301 @default.
• W2129164530 hasRelatedWork W2002120878 @default.
• W2129164530 hasRelatedWork W2003938723 @default.
• W2129164530 hasRelatedWork W2047967234 @default.
• W2129164530 hasRelatedWork W2118496982 @default.
• W2129164530 hasRelatedWork W2156028401 @default.
• W2129164530 hasRelatedWork W2167960661 @default.

• next